Daniel Waterkamp

10.7k citations
39 papers · 3.9k · 2 hit papers · h-index 21

Impact in

  • Oncology top 0.5%
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
    • Lung Cancer Research Studies
    • CAR-T cell therapy research
    • Lung Cancer Treatments and Mutations

Papers in

    • Cancer Immunotherapy and Biomarkers 26
    • Colorectal Cancer Treatments and Studies 19
    • Cancer Treatment and Pharmacology 7
    • Lung Cancer Research Studies 7
    • Lung Cancer Treatments and Mutations 9

Daniel Waterkamp

39 papers receiving 3.8k citations

Daniel Waterkamp's Hit Papers

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial 2016 · 2.1k citations
2.1k0+4+8Years since publication50010001.5k2.0k

Peers

Daniel Waterkamp
Comparison fields: 5 of 78
  • Oncology 3.5k
  • Pulmonary and Respiratory Medicine 1.9k
  • Hepatology 354
  • Immunology 813
  • Cancer Research 530
Replace Francesco Orlandi with:
Francesco Orlandi United States
Davey B. Daniel United States
Michael McCleod United States
Gene Grant Finley United States
Achim Rittmeyer United States
Vinod Ganju Australia
Laura S. Wood United States
Z. Alexander Cao United States
Andrew Weickhardt Australia
Venice Archer United Kingdom
Daniel Waterkamp relative to Francesco Orlandi United States Francesco Orlandi's profile →
Citations per field
00.5×100×200×344×
Francesco Orlandi · 1×
Citations per year

Countries citing papers authored by Daniel Waterkamp

Since Specialization
Citations

This map shows the geographic impact of Daniel Waterkamp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Waterkamp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Waterkamp more than expected).

Fields of papers citing papers by Daniel Waterkamp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Waterkamp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Waterkamp. The network helps show where Daniel Waterkamp may publish in the future.

Co-authors

The 25 scholars most cited alongside Daniel Waterkamp, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel Waterkamp Line = papers co-authored together Daniel Waterkamp links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Hit paper breakdown →
20162112
2
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
Hit paper breakdown →
2013438
3 2014225
4 2013176
5 2015103
6 201698
7 201586
8 201765
9 201761
10 201656
11 201549
12 201838
13 201637
14 201634
15 201533
16 201528
17 201627
18 201425
19 201724
20 201622

About Daniel Waterkamp

Daniel Waterkamp is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Pathology and Forensic Medicine and Hepatology, having authored 39 papers that have together received 3.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (26 papers), Colorectal Cancer Treatments and Studies (19 papers), Lung Cancer Treatments and Mutations (9 papers), Cancer Genomics and Diagnostics (8 papers), Cancer Treatment and Pharmacology (7 papers), Lung Cancer Research Studies (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). The work is most often cited by research in Oncology (3.5k citations), Pulmonary and Respiratory Medicine (1.9k citations), Hepatology (354 citations), Immunology (813 citations) and Cancer Research (530 citations). Daniel Waterkamp has collaborated with scholars based in United States, Switzerland and Spain. Frequent co-authors include Marcin Kowanetz, Achim Rittmeyer, Alexander I. Spira, Marcus Ballinger, Julien Mazières, Johan Vansteenkiste, Louis Fehrenbacher, Keunchil Park, Alan Sandler and Wei Zou. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, European Journal of Cancer and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact